Search Results

indications as filgrastim: to treat patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia (FN); patients with acute myeloid leukemia receiving induction or

associated with a 5% improvement in modified PFS but also higher rates of febrile neutropenia and neuropathy. The FDA indication approval recommends growth factor support with BV‐AVD. 8 The other issue to consider with these regimens is cost. Because of the

for oncologic emergencies are identified, such as evolving risk stratification paradigms for febrile neutropenia, observation status will likely play an increasing role. 20 The NCI has identified the management of oncologic emergencies as an important

. Crawford J Wolff DA Culakova E . First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: results from a prospective nationwide study [Abstract] . Blood 2004 ; 104 : 607a – 608a . Abstract #2210 . 75

Elser C . Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation . Ann Hematol 1998 ; 77 : 41 - 45 . 10 Bjerke JW Meyers JD

secondary AML.” One clinical caveat is that rates of myelosuppression and febrile neutropenia with infections were significantly higher for the combination regimen than for azacitidine alone, with many patients requiring close monitoring and frequent

significant differences in survival were seen among the 4 regimens. Patients receiving carboplatin and paclitaxel had a lower incidence of grade 3 and 4 nausea, vomiting, and febrile neutropenia. From this point on, carboplatin and paclitaxel became the most

included Table 1. CDK 4/6 Inhibitors neutropenia, anemia, and fatigue. No cases of febrile neutropenia were observed. However, an increased rate of grade 3/4 infections and pulmonary embolism was seen in the palbociclib/letrozole arm (5% vs 0

monitor WBC counts in patients receiving palbociclib and ribociclib, but those who develop neutropenia “generally don't feel the effects” and febrile neutropenia is uncommon, he indicated. “As we move forward,” he added, clinicians can expect “the coming

reduction from 300 to 200 mg. Febrile neutropenia is managed with antibiotics. There were no treatment-related deaths in the QUAZAR study. 6 The NCCN Guidelines do not have data on the use of FLT3 inhibitors posttransplant. Two randomized trials support